Cargando…

Clinical efficacy of low dose recombinant tissue-type plasminogen activator for the treatment of acute intermediate-risk pulmonary embolism

OBJECTIVES: To investigate the efficacy and safety of initial thrombolysis by recombinant tissue-type plasminogen activator (rt-PA) in compared with anticoagulant therapy in patients with acute intermediate-risk pulmonary embolism (PE). METHODS: Sixty-six patients with acute intermediate-risk PE wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ling-Yun, Gao, Bao-An, Jin, Zhu, Xiang, Guang-Ming, Gong, Zheng, Zhang, Ting-Ting, Lu, Hong-Fang, Wang, Yong-Quan, Gong, Yuan, Lu, Cheng, Huang, Wei-Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Saudi Medical Journal 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274653/ https://www.ncbi.nlm.nih.gov/pubmed/30397707 http://dx.doi.org/10.15537/smj.2018.11.22717

Ejemplares similares

Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism
por: Hoang, Bui Hai, et al.
Publicado: (2021)

Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism
por: Stubblefield, William B., et al.
Publicado: (2016)

Efficacy and Safety of Low Dose Recombinant Tissue-Type Plasminogen Activator for the Treatment of Acute Pulmonary Thromboembolism: A Randomized, Multicenter, Controlled Trial
por: Wang, Chen, et al.
Publicado: (2010)

Cardiopulmonary bypass and recombinant plasminogen activator for treatment of experimental fatal pulmonary embolism
por: Kjærgaard, B, et al.
Publicado: (2007)

Tissue plasminogen activator dose and pulmonary artery pressure reduction in catheter directed thrombolysis of submassive pulmonary embolism
por: Patel, Darshan C., et al.
Publicado: (2019)

Successful thrombolytic therapy with recombinant tissue-type plasminogen activator for massive pulmonary embolism -A case report-
por: Kim, Min Soo, et al.
Publicado: (2010)

Recombinant tissue plasminogen activator plus heparin compared with heparin alone for patients with acute submassive pulmonary embolism: one-year outcome
por: Mi, Yu-Hong, et al.
Publicado: (2013)

Tissue Plasminogen Activator Use in Cardiac Arrest Secondary to Fulminant Pulmonary Embolism
por: Yousuf, Tariq, et al.
Publicado: (2016)

Central Venous Catheter-directed Tissue Plasminogen Activator in Massive Pulmonary Embolism
por: Gulati, Vishal, et al.
Publicado: (2018)

Efficacy and Safety of Different Dosage of Recombinant Tissue-type Plasminogen Activator (rt-PA) in the Treatment of Acute Pulmonary Embolism: A Systematic Review and Meta-analysis
por: Amini, Shahideh, et al.
Publicado: (2021)

Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator
por: Ong, Cheung-Ter, et al.
Publicado: (2017)

Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant ADAMTS 13
por: Fan, Mengchen, et al.
Publicado: (2016)

Recombinant tissue plasminogen activator in the treatment of suprachoroidal hemorrhage
por: Kunjukunju, Nancy, et al.
Publicado: (2011)

Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis
por: Yang, Hung-Wei, et al.
Publicado: (2012)

Intermediate-High Risk Pulmonary Embolism
por: Mirambeaux, Rosa, et al.
Publicado: (2019)

Intermediate pulmonary embolism: Diagnosis and management
por: Davidson, Bruce L
Publicado: (2019)

Clinical efficacy and imaging evaluation of recombinant tissue plasminogen activator thrombolytic therapy in patients with wake up stroke: A randomized controlled trial
por: Zhang, Chun-Yang, et al.
Publicado: (2020)

Efficacy and safety of hydro-mechanical defragmentation in intermediate- and high-risk pulmonary embolism
por: Hassan, Ayman K. M., et al.
Publicado: (2021)

Enzymatic vitreolysis with recombinant tissue plasminogen activator for vitreomacular traction
por: Raczyńska, Dorota, et al.
Publicado: (2015)

Rosiglitazone ameliorates tissue plasminogen activator‐induced brain hemorrhage after stroke
por: Li, Yan, et al.
Publicado: (2019)

Effects of Concurrent Dosing on the Efficacy of Tissue Plasminogen Activator and Deoxyribonuclease in the Treatment of Pleural Infection
por: Pathak, Vikas, et al.
Publicado: (2023)

Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis
por: You, Shoujiang, et al.
Publicado: (2018)

Microcatheter-Directed Thrombolysis Using Recombinant Tissue Plasminogen Activator for the Treatment of Acute Superior Mesenteric Artery Embolism: A Case Report
por: Kim, Yang-Won, et al.
Publicado: (2023)

Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1
por: Gong, Lihu, et al.
Publicado: (2016)

Efficacy of Urinary Kallidinogenase Plus Intravenous Recombinant Tissue Plasminogen Activator for Stroke Patients With Extended Window: A Retrospective Analysis
por: Li, Xueyuan, et al.
Publicado: (2023)

Long-term stability of recombinant tissue plasminogen activator at -80 C
por: Shaw, George J, et al.
Publicado: (2009)

Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses
por: Bäumer, Wolfgang, et al.
Publicado: (2013)

Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series
por: Dybowska, Małgorzata, et al.
Publicado: (2020)

Outcomes of asymptomatic recombinant tissue plasminogen activator associated intracranial hemorrhage
por: Teekaput, Chutithep, et al.
Publicado: (2022)

Might life-threatening acute pulmonary edema occur after using recombinant tissue plasminogen activator? A case report
por: Chen, Xue-Bing, et al.
Publicado: (2021)

Soluble expression, purification, and characterization of active recombinant human tissue plasminogen activator by auto-induction in E. coli
por: Long, Xiaobin, et al.
Publicado: (2015)

The Impact of Loading Dose on Outcome in Stroke Patients Receiving Low-Dose Tissue Plasminogen Activator Thrombolytic Therapy
por: Wong, Yi-Sin, et al.
Publicado: (2020)

The Use of Low-Dose Recombinant Tissue Plasminogen Activator to Treat a Preterm Infant with an Intrauterine Spontaneous Arterial Thromboembolism
por: Demirelli, Yaşar, et al.
Publicado: (2015)

Minimally invasive treatment of complex collections: safety and efficacy of recombinant tissue plasminogen activator as an adjuvant to percutaneous drainage
por: Falsarella, Priscila Mina, et al.
Publicado: (2018)

Upper extremity acute compartment syndrome during tissue plasminogen activator therapy for pulmonary embolism in a morbidly obese patient
por: Tuna, Serkan, et al.
Publicado: (2015)

Low-dose thrombolytic therapy versus unfractionated heparin in patients with intermediate-high risk pulmonary embolism
por: Surgit, Ozgur, et al.
Publicado: (2023)

The Development of Pulmonary Edema after Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patient; Neurogenic or Non-Neurogenic?
por: Alwahdy, Ahmad Sulaiman, et al.
Publicado: (2022)

Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial
por: Sanchez, Olivier, et al.
Publicado: (2021)

Efficacy of low-dose rivaroxaban in an 88-year-old female with pulmonary embolism: A case report
por: Zhou, Huanyu, et al.
Publicado: (2019)

Association between serum calcium and prognosis in patients with acute pulmonary embolism and the optimization of pulmonary embolism severity index
por: Wang, Xin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2iv9t4cutu7flk51k5ge8qlkn0